CHPG

CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways.

Product information

CAS Number: 170846-74-9

Molecular Weight: 201.61

Formula: C8H8ClNO3

Chemical Name: 2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid

Smiles: NC(C1=CC(O)=CC=C1Cl)C(O)=O

InChiKey: UNIDAFCQFPGYJJ-UHFFFAOYSA-N

InChi: InChI=1S/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

CHPG (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment. CHPG (0.5 mM; 30 mins ) protects BV2 cells against SO2-induced apoptosis. CHPG (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels.

In Vivo:

CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume.

References:

1. Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52.

Products are for research use only. Not for human use.